Tango Therapeutics Inc. has disclosed the discovery of TNG-348, an orally active, potent, reversible allosteric inhibitor of the USP1 deubiquitinating enzyme.
Methylthioadenosine phosphorylase (MTAP) is an enzyme ubiquitously expressed in all tissues. MTAP homozygous deletion occurs in 10-15% of different cancers such as leukemia, lymphoma, lung, brain, breast and others.
Tango Therapeutics Inc. has patented histone-lysine N-methyltransferase EHMT1 (H3-K9-HMTase 5; GLP) and/or EHMT2 inhibitors reported to be useful for the treatment of cancer, sickle cell disease and β-thalassemia.
The FDA has cleared Tango Therapeutics Inc.'s IND application for TNG-462, a next-generation methylthioadenosine-cooperative (MTA) inhibitor of protein arginine methyl transferase 5 (PRMT5) for the treatment of cancers with methylthioadenosine phosphorylase (MTAP) deletion.
The stock rally by Tango Therapeutics Inc. over the past month or so has further revved the long-percolating interest in protein arginine methyl transferase 5 (PRMT5) and in synthetic lethality, where a number of parties have programs ongoing.
The start of a phase Ib/II trial with nanatinostat by Viracta Therapeutics Inc. has brought new attention to the burgeoning field of synthetic lethality, where a number of players are piquing the interest of Wall Street.
Less than a year after landing a multibillion-dollar deal expansion with partner Gilead Sciences Inc., targeted cancer drug developer Tango Therapeutics Inc. is making moves to go public via a merger with Boxer Capital LLC-sponsored special purpose acquisition company BCTG Acquisition Corp.
Tango Therapeutics Inc. CEO Barbara Weber told BioWorld that Gilead Sciences Inc.’s decision to greatly expand their 2018 deal in oncology – a pact then valued as high as $1.7 billion – was based on brisker than expected progress in the original, five-target effort.